The effectiveness of antibody-based therapies, including trastuzumab and bevacizumab, in breast cancer is well established, and the importance of the immune system in cancer development was highlighted once again by studies using inhibitors of immune checkpoint pathway components such as PD-1, PD-L1, and CTLA-4. This evidence concerns the gene CTLA4 and cancer.